Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy
Saved in:
| Main Authors: | Suravi Raychaudhuri, Megan Othus, Mary-Elizabeth M. Percival, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, Jacob S. Appelbaum |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Blood Neoplasia |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950328025000640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Graft-<i>versus</i>-leukemia
by: Frederick R. Appelbaum
Published: (2025-06-01) -
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm
by: Suravi Raychaudhuri, et al.
Published: (2025-08-01) -
Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
by: Stephen E. Langabeer, et al.
Published: (2020-01-01) -
6-month survival of patients with acute myeloid leukemia who received modified chemotherapy at Wahidin Sudirohusodo Hospital
by: Edwinda D. Ratu, et al.
Published: (2024-09-01) -
Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samples
by: Suravi Raychaudhuri, et al.
Published: (2025-05-01)